Explore the latest advances in RSV vaccine research, and what these developments mean for prevention and public health.

As gene and cell therapies mature, developers are increasingly looking beyond existing delivery systems to address challenges around targeting, immunogenicity, manufacturability, and cost. Dr. Angelo ...

Discover how arbovirus E Dimer vaccines are engineered to improve safety by minimizing antibody dependent enhancement.

Phase 4 COMPARE trial data show Nuvaxovid was associated with lower reactogenicity and fewer daily activity disruptions than mNEXSPIKE.

(MENAFN- ALA Group) Sister companies aim to strengthen collaborations with biotech and pharmaceutical companies across South Korea and Asia by offering over two decades of expertise in biosafety and ...

The Virginia Commonwealth University researchers behind one of the most widely-used canine Lyme disease vaccines are ...

Globally, RSV is responsible for an immense health and economic burden, causing an estimated 33 million new ALRI cases and ...

RT-MALS can provide instantaneous measurements of adenovirus particle size and titer during downstream and fill–finish ...

Neoantigens are peptides derived from patient-specific and tumor-specific mutations, which can be recognized by the immune system and mediate tumor recognition that leads to immune destruction of the ...

Chemical engineers develop products and processes that improve the well-being of humanity and touch every aspect of our lives. From discovering new materials and developing new vaccines to solving ...